NVSNovartis AG

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Vasant Narasimhan

Location

N/A, Switzerland

Exchange

NYSE

Website

https://novartis.com

Summary

Novartis AG researches, develops, manufactures, and markets healthcare products.

Company Info

CEO

Vasant Narasimhan

Location

N/A, Switzerland

Exchange

NYSE

Website

https://novartis.com

Summary

Novartis AG researches, develops, manufactures, and markets healthcare products.

AI Insights for NVS
5 min read

Quick Summary

Novartis AG is a Switzerland-based global healthcare company headquartered in Basel and traded on the NYSE as NVS through a depositary receipt structure. The company researches, develops, manufactures, and markets pharmaceutical products, with a primary focus on innovative medicines across cardiovascular, oncology, immunology, neuroscience, renal, and other specialty areas. Its reported operations include Innovative Medicines and Sandoz, with Sandoz described as supplying finished-dose medicines, active pharmaceutical ingredients, and small-molecule pharmaceutical products. Novartis sells branded prescription drugs, specialty therapies, and selected generic or biosimilar-related products through healthcare systems around the world. Its main customers include hospitals, physicians, pharmacies, wholesalers, government health programs, private insurers, pharmacy benefit managers, and patients who rely on long-term treatment for chronic or severe diseases.

Strengths

•

Novartis’ main strength is its scale as a global pharmaceutical company with about $56.7 billion in total revenue, nearly $14.0 billion in net income, and more than 100,000 employees.

•

The company has a broad portfolio of growth brands across oncology, immunology, neuroscience, cardiovascular disease, and radioligand therapy, which reduces dependence on any single therapeutic area.

•

Its dividend yield of roughly 3.3% and history of dividend increases make it attractive to income-oriented investors seeking defensive healthcare exposure.

•

Novartis also has strong research and development capabilities, global regulatory experience, and the financial capacity to pursue large acquisitions or licensing deals.

•

Its low beta suggests the shares may be less volatile than the broader market, which can be valuable during uncertain macroeconomic or market conditions.

Key Risks

•

Novartis faces substantial risks from patent cliffs, generic competition, and pricing pressure from governments, insurers, and pharmacy benefit managers.

•

Drug development risk is high because late-stage clinical failures can destroy expected revenue streams and reduce confidence in management’s pipeline strategy, as seen with pelacarsen.

•

Regulatory risk is also important because approvals, label restrictions, safety warnings, or reimbursement delays can materially change the commercial outlook for a product.

•

Acquisition risk could rise if Novartis pays high prices for biotech assets that later fail to meet clinical, regulatory, or sales expectations.

What to Watch

During the most recent reported quarter, Novartis delivered stronger-than-expected core EPS but missed revenue expectations, highlighting a mixed operating picture.
The company’s Q4 core EPS rose to $2.03, while revenue of $13.3 billion came in below estimates because older products such as Entresto and Promacta faced generic competition.
Growth brands including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Scemblix helped support the quarter and showed that the company’s newer portfolio is gaining traction.
Management guided for low single-digit sales growth in 2026 after 2025 sales rose 8% to about $54.5 billion.
The quarter also featured strategic portfolio activity, including the pursuit of a $12 billion Avidity deal in neuroscience, reported interest in Cytokinetics for cardiovascular expansion, and continued operational reshaping through planned workforce reductions in East Hanover.

Price Drivers

•

Novartis’ stock price is driven by earnings growth, drug sales momentum, pipeline results, dividend expectations, and investor confidence in management’s ability to offset patent losses.

•

The company reported Q4 core EPS of $2.03 that beat estimates, but revenue of $13.3 billion missed expectations because Entresto and Promacta faced generic competition.

•

Growth in Cosentyx, Kisqali, Kesimpta, Pluvicto, and Scemblix helped offset some of those pressures, which is important because investors want evidence that newer brands can replace maturing products.

•

Valuation also matters because the stock trades at about 19.6 times earnings, with an earnings yield near 5.1%, an EV/EBITDA ratio near 16.9, and a dividend yield around 3.3%.

•

The low beta of 0.468 can make NVS attractive to defensive investors, but major clinical trial failures, acquisition news, currency moves, healthcare policy changes, and pharmaceutical pricing pressure can still move the shares materially.

Recent News

•

Recent news around Novartis has been active and focused on earnings, pipeline development, acquisitions, divestitures, and restructuring.

•

The company reported Q4 core EPS of $2.03, beating estimates, but revenue missed as Entresto and Promacta faced generic competition.

•

Reports indicated that Novartis may be interested in acquiring Cytokinetics to strengthen its cardiovascular pipeline, especially through aficamten, a late-stage hypertrophic cardiomyopathy drug.

•

Novartis is also pursuing a $12 billion Avidity deal to boost neuroscience and previously agreed to acquire Chinook Therapeutics for up to $3.5 billion to expand its kidney-disease pipeline.

•

Other news included layoffs at the East Hanover, New Jersey headquarters, the sale of its stake in Novartis India to investment groups, promising remibrutinib Phase 3 results, and a negative pelacarsen late-stage trial outcome.

Market Trends

•

The pharmaceutical market is being shaped by aging populations, growing chronic disease burdens, rising demand for specialty medicines, and increasing pressure from patent expirations.

•

Large drugmakers are pursuing acquisitions and partnerships because they need new growth sources as blockbuster products lose exclusivity and face generic or biosimilar competition.

•

Oncology, immunology, neuroscience, cardiovascular disease, obesity, and rare disease remain especially competitive areas for investment and clinical development.

•

At the same time, governments and payers are pushing back on drug prices, which can limit revenue growth even for successful therapies.

•

Defensive healthcare stocks with dividends, diversified pipelines, and steady cash flow remain attractive to many investors, but clinical setbacks, regulatory decisions, and policy changes can still create major volatility.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on NVS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@Altruistic_Dr2 9 months ago

SCOTUS struck down Trump's IEEPA tariffs, but he's already replacing them using Section 122

SCOTUS struck down Trump's IEEPA tariffs, but he's already replacing them using Section 122

post thumbnail
avatar
@Altruistic_Dr2 9 months ago

Goldman Sachs predicts international stocks will outperform the S&P 500 over the next decade

Goldman Sachs predicts international stocks will outperform the S&P 500 over the next decade

post thumbnail
avatar
@General-Mils 10 months ago

Market recap: Canada facing 100% tariffs, Greenland dispute settled, and updates from Davos

Market recap: Canada facing 100% tariffs, Greenland dispute settled, and updates from Davos

post thumbnail
avatar
@UndyingValue 10 months ago

Trump threatens Canada with 100% tariffs but drops EU threats after NATO deal

Trump threatens Canada with 100% tariffs but drops EU threats after NATO deal

post thumbnail
avatar
@democratiCrayn 10 months ago

Trump cancels planned EU tariffs after NATO meeting regarding Greenland

Trump cancels planned EU tariffs after NATO meeting regarding Greenland

post thumbnail
avatar
@General-Mils 10 months ago

gMG market outlook and upcoming pipeline therapies

gMG market outlook and upcoming pipeline therapies

post thumbnail
avatar
@ShallowLoving 11 months ago

Trump admin signs pricing and tariff deals with 9 major pharma companies

Trump admin signs pricing and tariff deals with 9 major pharma companies

post thumbnail
avatar
@Ok_West_5560 11 months ago

Precision medicine market projected to reach $537B by 2035

Precision medicine market projected to reach $537B by 2035

post thumbnail
avatar
@Simonwhite 12 months ago

Which pharma company is better?

Which pharma company is better?

vs : with a similar market cap and revenue, which one's better? NVS has a yield of 3.1% while MRK also catches up with a yield of ~2.7%. MRK's only downside would probably be a higher drug concentration risk with Keytruda. What do y'all think?

avatar
@kewur 1 year ago

Biologic Therapies Driving Growth in Global Microscopic Polyangiitis (MPA) Market

Biologic Therapies Driving Growth in Global Microscopic Polyangiitis (MPA) Market

post thumbnail